| Literature DB >> 32585491 |
Michael A Sugarman1, Henrik Zetterberg2, Kaj Blennow3, Yorghos Tripodis4, Ann C McKee5, Thor D Stein6, Brett Martin7, Joseph N Palmisano7, Eric G Steinberg8, Irene Simkin9, Andrew E Budson10, Ronald Killiany11, Maureen K O'Connor1, Rhoda Au12, Wendy Wei Qiao Qiu13, Lee E Goldstein14, Neil W Kowall15, Jesse Mez16, Robert A Stern17, Michael L Alosco18.
Abstract
We examined baseline and longitudinal associations between plasma neurofilament light (NfL) and total tau (t-tau), and the clinical presentation of Alzheimer's disease (AD). A total of 579 participants (238, normal cognition [NC]; 185, mild cognitive impairment [MCI]; 156, AD dementia) had baseline blood draws; 82% had follow-up evaluations. Plasma samples were analyzed for NfL and t-tau using Simoa technology. Baseline plasma NfL was higher in AD dementia than MCI (standardized mean difference = 0.55, 95% CI: 0.37-0.73) and NC (standardized mean difference = 0.68, 95% CI: 0.49-0.88), corresponded to Clinical Dementia Rating scores (OR = 1.94, 95% CI: 1.35-2.79]), and correlated with all neuropsychological tests (r's = 0.13-0.42). Longitudinally, NfL did not predict diagnostic conversion but predicted decline on 3/10 neuropsychological tests. Baseline plasma t-tau was higher in AD dementia than NC with a small effect (standardized mean difference = 0.33, 95% CI: 0.10-0.57) but not MCI. t-tau did not statistically significant predict any longitudinal outcomes. Plasma NfL may be useful for the detection of AD dementia and monitoring of disease progression. In contrast, there was minimal evidence in support of plasma t-tau.Entities:
Keywords: Alzheimer's disease; Neurofilament light; Plasma biomarkers; Total tau
Mesh:
Substances:
Year: 2020 PMID: 32585491 PMCID: PMC7484086 DOI: 10.1016/j.neurobiolaging.2020.05.011
Source DB: PubMed Journal: Neurobiol Aging ISSN: 0197-4580 Impact factor: 4.673